AgingResearch.NewsJoin free

Secondary prevention medication classes (statins, beta-blockers, ACE inhibitors or ARBs)

Secondary prevention medication classes (statins, beta-blockers, ACE inhibitors or ARBs) has been studied in 1 paper since 2016: 1 observational study in people. The newest paper, Mar 1, 2016: “Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction”.

Exposure

1 paper studies it1 findingUpdated

See all 1 papers on secondary prevention medication classes (statins, beta-blockers, ACE inhibitors or ARBs)

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Individuals taking all three classes of medication were 30% less likely to die within 12 months than those not taking guideline medications (aHR = 0.70, 95% CI = 0.67-0.73)”
Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial InfarctionJournal of the American Geriatrics Society2016doi:10.1111/jgs.13953
Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Agency for Healthcare Research and Quality and 2 more
  • 1 of 1 finding with company ties
  • Humans1

What is secondary prevention medication classes (statins, beta-blockers, ACE inhibitors or ARBs) linked with?

1

Studies link secondary prevention medication classes (statins, beta-blockers, ACE inhibitors or ARBs) with 12-month mortality.

12-month mortality

downin humans1

1 study

  1. Secondary prevention medication classes (statins, beta-blockers, ACE inhibitors or ARBs) is linked with a lower risk of 12-month mortality in humans (taking all three medication classes versus none) (aHR 0.70 (95% CI 0.67-0.73)).

    “Individuals taking all three classes of medication were 30% less likely to die within 12 months than those not taking guideline medications (aHR = 0.70, 95% CI = 0.67-0.73)”

    Humanstaking all three medication classes versus none12 monthsn = 184,156

    Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction

    Journal of the American Geriatrics Society

Latest

Related